ALSUC in refractory GERD
Phase 3
Recruiting
- Conditions
- GERD.Gastro-esophageal reflux disease
- Registration Number
- IRCT20211203053263N3
- Lead Sponsor
- Ilam University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Patients who remained symptomatic (assessed by daily reflux questionnaire) with a standard dose of PPI after a trial period of treatment of at least 2 months.
Exclusion Criteria
non-compliant
inappropriate use of PPI
Other diseases that can mimic the symptoms of GERD include achalasia, eosinophilic esophagitis, infectious esophagitis, pill esophagitis, gastroparesis, and esophageal stricture or cancer and functional dyspepsia according to the Rome4 criteria.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method GERD symptoms severity and frequency during and 6 weeks after treatment. Timepoint: During intervention and 6 weeks after treatment. Method of measurement: Questionnaire.
- Secondary Outcome Measures
Name Time Method Compliance of patient. Timepoint: During intervention. Method of measurement: Questionnaire.